伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EXEL 伊克力西斯

盘后交易 07-01 19:19:54 EDT

53.96

-0.45

-0.83%

盘后54.50

+0.54+1.00%

17:23 EDT

最高54.47	最低53.25	成交量184.32万
今开54.20	昨收54.41	日振幅2.25%
总市值135.44亿	流通市值111.16亿	总股本2.51亿
成交额9,931万	换手率0.89%	流通股本2.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"伊克力西斯","latestPrice":53.96,"timestamp":1782936000000,"preClose":54.41,"halted":0,"volume":1843238,"hourTrading":{"tag":"盘后","latestPrice":54.5,"preClose":53.96,"latestTime":"17:23 EDT","volume":48477,"amount":2615853.435624,"timestamp":1782941022396,"change":0.54,"changeRate":0.010007,"amplitude":0.010007},"delay":0,"changeRate":-0.008270538503951402,"floatShares":206000000,"shares":250999999,"eps":3.022839,"marketStatus":"盘后交易","change":-0.45,"latestTime":"07-01 19:19:54 EDT","open":54.2,"high":54.4712,"low":53.2481,"amount":99306543.011606,"amplitude":0.022479,"askPrice":54.5,"askSize":1000,"bidPrice":53.14,"bidSize":4,"shortable":3,"etf":0,"ttmEps":3.022839,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782950400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":54.41,"preHourTrading":{"tag":"盘前","latestPrice":54.06,"preClose":54.41,"latestTime":"09:26 EDT","volume":8469,"amount":460814.88924,"timestamp":1782912392081,"change":-0.35,"changeRate":-0.006433,"amplitude":0.025731},"postHourTrading":{"tag":"盘后","latestPrice":54.5,"preClose":53.96,"latestTime":"17:23 EDT","volume":48477,"amount":2615853.435624,"timestamp":1782941022396,"change":0.54,"changeRate":0.010007,"amplitude":0.010007},"volumeRatio":0.532528,"impliedVol":0.385,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/EXEL","defaultTab":"news","newsList":[{"id":"1166319039","title":"伊克力西斯公布Zanzalintinib联合免疫检查点抑制剂治疗转移性结直肠癌的III期Stellar-303试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1166319039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166319039?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:02","pubTimestamp":1782129739,"startTime":"0","endTime":"0","summary":"伊克力西斯公司近日公布了其III期Stellar-303临床试验的最新情况。该试验旨在评估Zanzalintinib与一种免疫检查点抑制剂联合疗法，在治疗转移性结直肠癌患者中的疗效与安全性。这一更新为关注该药物研发进程的投资者与医学界提供了重要信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXEL","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163935567","title":"伊克力西斯：Cabometyx在非功能性神经内分泌肿瘤中降低进展或死亡风险74%，在功能性肿瘤中降低60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163935567","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163935567?lang=zh_cn&edition=full","pubTime":"2026-05-30 22:04","pubTimestamp":1780149862,"startTime":"0","endTime":"0","summary":"伊克力西斯（Exelixis）宣布，其药物卡博替尼（Cabometyx）在治疗神经内分泌肿瘤方面取得了积极成果。数据显示，该药物在非功能性神经内分泌肿瘤患者中，将疾病进展或死亡的风险显著降低了74%。同时，在功能性神经内分泌肿瘤患者群体中，这一风险降低幅度也达到了60%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176630342","title":"异动解读｜伊克力西斯盘中上涨5.54%，报52.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176630342","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176630342?lang=zh_cn&edition=full","pubTime":"2026-05-29 00:15","pubTimestamp":1779984910,"startTime":"0","endTime":"0","summary":"5月28日，伊克力西斯盘中上涨5.54%，报52.80美元/股，成交额6089.71万美元。伊克力西斯所在的生物科技行业中，个股表现分化，其中艾伯维公司涨1.34%，Natera涨1.12%，吉利德科学涨1.02%，再生元制药公司跌0.42%，安进跌0.35%。伊克力西斯是一家专注于癌症小分子治疗的生物科技公司，已推出包括卡博替尼在内的四款上市药品，其主要临床候选药物赞扎替尼目前正在接受FDA审查，用于治疗特定类型的结直肠癌。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120255073","title":"伊克力西斯与默克就结直肠癌三期关键试验Stellar-316达成临床开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1120255073","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120255073?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:01","pubTimestamp":1779192103,"startTime":"0","endTime":"0","summary":"伊克力西斯宣布，将与默克公司就一项针对结直肠癌患者的三期关键试验Stellar-316展开临床开发合作。该合作标志着双方在肿瘤治疗领域的重要战略布局，旨在加速创新疗法的临床评估进程，为患者带来新的希望。试验的推进将结合双方在药物研发与临床运营方面的专长，共同探索更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","EXEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177100178","title":"财报前瞻｜伊克力西斯本季度营收预计增21.51%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1177100178","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177100178?lang=zh_cn&edition=full","pubTime":"2026-04-28 10:43","pubTimestamp":1777344218,"startTime":"0","endTime":"0","summary":"伊克力西斯将于2026年05月05日发布最新季度财报，市场更关注营收与利润的同比改善节奏及产品管线推进对盈利结构的影响。市场一致预期本季度伊克力西斯营收为6.05亿美元，同比增长21.51%；调整后每股收益为0.72美元，同比增长98.10%；当前一致预期未提供本季度毛利率与净利润或净利率的具体预测值。当前一致预期显示，本季度营收将达到6.05亿美元，同比提升21.51%，增长动能仍主要来自核心净产品的稳定放量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜伊克力西斯本季度营收预计增21.51%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150975700","title":"财报前瞻｜伊克力西斯本季度营收预计小幅增长，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1150975700","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150975700?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:29","pubTimestamp":1770085778,"startTime":"0","endTime":"0","summary":"伊克力西斯将于2026年02月10日发布财报，市场普遍预计营收与盈利保持增长，关注核心产品与管线推进对利润率的影响。市场一致预期显示，本季度伊克力西斯总收入预计为6.04亿美元，同比增长7.19%；调整后每股收益预计为0.76美元，同比增长78.95%；息税前利润预计为2.15亿美元，同比增长53.35%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜伊克力西斯本季度营收预计小幅增长，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102099826","title":"伊克力西斯宣布美国FDA受理Zanzalintinib联合免疫检查点抑制剂治疗转移性结直肠癌的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1102099826","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102099826?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:03","pubTimestamp":1770037432,"startTime":"0","endTime":"0","summary":"伊克力西斯 (Exelixis) 宣布，美国食品药品监督管理局（FDA）已正式受理其新药Zanzalintinib与一种免疫检查点抑制剂联合用药的新药申请。该治疗方案拟用于转移性结直肠癌患者。\n这一监管进展标志着该联合疗法在针对这一难治癌症的研发道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","EXEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177048004","title":"伊克力西斯公布2025财年初步业绩，发布2026年财务指引并规划年度重点与里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177048004","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177048004?lang=zh_cn&edition=full","pubTime":"2026-01-12 05:01","pubTimestamp":1768165274,"startTime":"0","endTime":"0","summary":"伊克力西斯（Exelixis）近日披露了其2025财年的初步财务数据，同时向市场提供了针对2026财年的财务业绩展望。此外，公司还详细阐述了2026年的核心战略重点与关键发展里程碑，为投资者勾勒出清晰的发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110382268","title":"伊克力西斯与Natera就结直肠癌药物Zanzalintinib的关键性III期试验Stellar-316达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1110382268","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110382268?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:03","pubTimestamp":1767791008,"startTime":"0","endTime":"0","summary":"伊克力西斯与Natera公司宣布将开展战略合作，共同推进名为Stellar-316的III期关键性临床试验。该试验旨在评估Zanzalintinib针对结直肠癌患者的疗效与安全性，标志着双方在肿瘤治疗领域的重要布局。此次合作将整合伊克力西斯在靶向药物研发方面的优势与Natera在精准诊断技术领域的专长，为结直肠癌治疗探索新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU0106261612.USD","LU2065171402.SGD","LU2065170008.USD","LU0012050646.USD","NTRA","BK4139","LU0963586101.USD","EXEL","LU2065169927.USD","LU2065171311.SGD","LU1988902786.USD","BK4532","LU0345770308.USD","LU1064131342.USD","LU2065731478.USD","LU2324357040.USD","LU0053671581.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513911742","title":"伊克力西斯盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513911742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513911742?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:53","pubTimestamp":1740149583,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时53分，伊克力西斯股票出现波动，股价急速上涨5.04%。截至发稿，该股报36.86美元/股，成交量41.3734万股，换手率0.15%，振幅2.79%。机构评级方面，在所有23家参与评级的机构中，57%的券商给予买入建议，39%的券商给予持有建议，4%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中，整体涨幅为0.28%。伊克力西斯公司简介：Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221225303a24eb5e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221225303a24eb5e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511236670","title":"伊克力西斯2024财年实现净利润5.21亿美元，同比增加150.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511236670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511236670?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:00","pubTimestamp":1739635242,"startTime":"0","endTime":"0","summary":"2月16日，伊克力西斯公布财报，公告显示公司2024财年净利润为5.21亿美元，同比增加150.48%；其中营业收入为21.69亿美元，同比增加18.52%，每股基本收益为1.80美元。从资产负债表来看，伊克力西斯总负债7.43亿美元，其中短期债务25.01百万美元，资产负债比为4.03，流动比率为3.64。机构评级：截至2025年2月16日，当前有22家机构对伊克力西斯目标价做出预测，其中目标均价为37.00美元，其中最低目标价为23.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000048a247299f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000048a247299f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199811140","title":"异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199811140","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199811140?lang=zh_cn&edition=full","pubTime":"2025-02-14 03:14","pubTimestamp":1739474073,"startTime":"0","endTime":"0","summary":"伊克力西斯(EXEL)周四盘中大涨5%,引发市场高度关注。\n\n消息方面,巴克莱重申对伊克力西斯评级为持股观望,但同时上调其目标价从25美元升至29美元。外资机构上调目标价,反映外界对该公司前景看好。\n\n分析人士表示,此举有望支撑伊克力西斯短期内股价表现,为公司的发展带来资金利好。不过公司未来能否持续获利,仍需观察其项目进展情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511579424","title":"伊克力西斯盘中异动 大幅上涨5.00%报34.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511579424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511579424?lang=zh_cn&edition=full","pubTime":"2025-02-14 03:11","pubTimestamp":1739473888,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日03时11分，伊克力西斯股票出现异动，股价大幅上涨5.00%。截至发稿，该股报34.44美元/股，成交量194.72万股，换手率0.70%，振幅4.86%。最近的财报数据显示，该股实现营业收入21.69亿美元，净利润5.21亿美元，每股收益1.80美元，毛利20.92亿美元，市盈率19.56倍。机构评级方面，在所有23家参与评级的机构中，57%的券商给予买入建议，39%的券商给予持有建议，4%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中，整体涨幅为1.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214031128a244e279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214031128a244e279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EXEL","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511524526","title":"巴克莱：维持Exelixis(EXEL.US)评级，由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524526","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511524526?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:42","pubTimestamp":1739461332,"startTime":"0","endTime":"0","summary":"巴克莱：维持Exelixis(EXEL.US)评级，由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13234248149779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510701123","title":"Piper Sandler：维持Exelixis(EXEL.US)评级，由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510701123","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510701123?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370757,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持Exelixis(EXEL.US)评级，由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12223248121874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506830219","title":"Truist Securities：维持Exelixis(EXEL.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506830219","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506830219?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:41","pubTimestamp":1737996075,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Exelixis(EXEL.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28004147864325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506035203","title":"Stephens & Co.：重申Exelixis(EXEL.US)评级，由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506035203","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506035203?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:41","pubTimestamp":1737988903,"startTime":"0","endTime":"0","summary":"Stephens & Co.：重申Exelixis(EXEL.US)评级，由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27224147863497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506741193","title":"HC Wainwright & Co.：重申Exelixis(EXEL.US)评级，由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506741193","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506741193?lang=zh_cn&edition=full","pubTime":"2025-01-27 21:04","pubTimestamp":1737983042,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Exelixis(EXEL.US)评级，由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27210447861282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506322004","title":"大摩：上调Exelixis(EXEL.US)评级，由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506322004","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506322004?lang=zh_cn&edition=full","pubTime":"2025-01-27 18:22","pubTimestamp":1737973324,"startTime":"0","endTime":"0","summary":"大摩：上调Exelixis(EXEL.US)评级，由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27182247851022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exelixis.com","stockEarnings":[{"period":"1week","weight":0.0598},{"period":"1month","weight":0.0779},{"period":"3month","weight":0.2355},{"period":"6month","weight":0.2414},{"period":"1year","weight":0.2345},{"period":"ytd","weight":0.2414}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Exelixis, Inc.是一家生物科技公司，致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司，并于2000年2月改为Exelixis股份有限公司。该公司已推出四款上市药品，其中包括其旗舰分子卡博替尼的两种制剂。Exelixis 正在积极推进其产品线，其主要临床候选药物赞扎替尼目前正在接受美国食品药品监督管理局 (FDA) 的审查，用于治疗特定类型的结直肠癌 (CRC)。该公司还拥有一个庞大的后期临床开发项目，旨在开发其他适应症。凭借理性严谨的投资策略，Exelixis 利用其内部专业知识和强大的战略合作伙伴关系，在包括小分子药物和生物疗法（例如抗体药物偶联物 (ADC)）在内的各种科学领域中寻找并把握机遇。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014932},{"month":2,"riseRate":0.5,"avgChangeRate":0.022968},{"month":3,"riseRate":0.5,"avgChangeRate":-0.011342},{"month":4,"riseRate":0.576923,"avgChangeRate":0.052902},{"month":5,"riseRate":0.481481,"avgChangeRate":0.008303},{"month":6,"riseRate":0.592593,"avgChangeRate":0.028178},{"month":7,"riseRate":0.538462,"avgChangeRate":0.042251},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.009406},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.037422},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.005954},{"month":11,"riseRate":0.615385,"avgChangeRate":0.062892},{"month":12,"riseRate":0.615385,"avgChangeRate":0.051791}],"exchange":"NASDAQ","name":"伊克力西斯","nameEN":"Exelixis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伊克力西斯,EXEL,伊克力西斯股票,伊克力西斯股票老虎,伊克力西斯股票老虎国际,伊克力西斯行情,伊克力西斯股票行情,伊克力西斯股价,伊克力西斯股市,伊克力西斯股票价格,伊克力西斯股票交易,伊克力西斯股票购买,伊克力西斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}